The authors gratefully acknowledge the generous financial support of the following sources: NIH grant NCI R01CA214608 (grant to E. S. F). We would like to thank members of Fischer and Ebert Lab at Dana-Farber Cancer Institute for useful discussions on development and optimization of these protocols.
Conflict of Interest: E.S.F. is a founder, scientific advisory board (SAB), and equity holder in Civetta Therapeutics, Jengu Therapeutics (board member), and Neomorph, Inc. E.S.F. is an equity holder in C4 Therapeutics and a consultant to Novartis, Sanofi, EcoR1 capital, Deerfield and Astellas. The Fischer lab receives or has received research funding from Novartis, Ajax and Astellas.